Land rights activism and the struggle for power: Overlapping of the non-profit sector and the political sphere in Uganda

This paper is about politics in Western Uganda and the multiple ways it relates to organizations of activists working on human rights issues. It draws examples from a local organization dealing with illegal expropriations of land in the region. As land grabbing is pervading in Ugandan society, land rights defenders deal with actors from a large sociological spectrum, from poor farmers to top-level politicians. Advocating human rights againstland grabbing entices exposure and risks

Post-Cotonou and the EU-African relationship A green light for a renewed cooperation? Bruges Political Research Papers 77/2019

The Cotonou Partnership Agreement, signed in 2000 and set to expire in 2020, is allegedly the most advanced collaboration between the EU and some of the lowest-income countries in the world. In practice, however, its achievements are meagre and contested. Nonetheless, the EU and ACP countries officially launched in 2018 the negotiation of the post-Cotonou agreement, which aims to deepen the Cotonou’s acquis. While environmental concerns in the EU-Africa relation often fall under the radar of scientific literature, this paper aims to show how the prism of environmental and climate mainstreaming helps in explaining the declining relevance of the post-Cotonou framework. Even though a rhetoric of a ‘deepened partnership’ became the leitmotiv of post-Cotonou, ‘far reaching’ environmental provisions in the future agreement are impeded by structural deficiencies. This reflects in post-Cotonou’s current draft, trying hard to push environmental ambitions but maintaining a ‘coherence’ between regional protocols that is detrimental to any real environmental mainstreaming progresses. A ‘greener’ post-Cotonou will be achieved only if references to other external policies are made due to the progressive ‘externalisation’ of Cotonou’s original pillars: political dialogue, trade and development cooperation into other agreements reducing therefore post-Cotonou’s added-value to a minimal

Land rights activism and the struggle for power: Overlapping of the non-profit sector and the political sphere in Uganda

This paper is about politics in Western Uganda and the multiple ways it relates to organizations of activists working on human rights issues. It draws examples from a local organization dealing with illegal expropriations of land in the region. As land grabbing is pervading in Ugandan society, land rights defenders deal with actors from a large sociological spectrum, from poor farmers to top-level politicians. Advocating human rights againstland grabbing entices exposure and risks

Land rights activism and the struggle for power: Overlapping of the non-profit sector and the political sphere in Uganda

This paper is about politics in Western Uganda and the multiple ways it relates to organizations of activists working on human rights issues. It draws examples from a local organization dealing with illegal expropriations of land in the region. As land grabbing is pervading in Ugandan society, land rights defenders deal with actors from a large sociological spectrum, from poor farmers to top-level politicians. Advocating human rights againstland grabbing entices exposure and risks

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)